Duloxetine

Duloxetine is an antidepressant of the serotonin-norepinephrine reuptake inhibitor class, commonly abbreviated SNRI ^[3]. It is a fairly balanced inhibitor of the reuptake of both serotonin and norepinephrine and, apart from these actions, has little effect on other receptors or channels ^[3]. Developed by Eli Lilly and Company, it was approved in the United States in 2004 and is best known under the brand name Cymbalta ^[1].

The drug is approved for a notably broad set of conditions that span psychiatry and pain medicine ^[3]. In mental health it is used for major depressive disorder and generalized anxiety disorder, and in pain management it is used for diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain; in Europe it is also approved for stress urinary incontinence ^[3]. A large network meta-analysis comparing antidepressants found duloxetine to be more effective than placebo for depression, with efficacy broadly comparable to other commonly used agents, although it was among the drugs with higher rates of discontinuation ^[1].

Duloxetine's usefulness in pain has been examined in systematic reviews ^[2]. A Cochrane review concluded that it is effective for the short-term treatment of painful diabetic neuropathy and provides benefit in fibromyalgia and in the physical pain that can accompany depression, though the size of the effect is modest and side effects are common ^[2]. These pain-relieving effects are thought to reflect the role of serotonin and norepinephrine in the nerve pathways that dampen pain signals ^[2].

Duloxetine is taken by mouth as a delayed-release capsule and has been available as a generic medicine since 2013 ^[3]. It is a prescription-only drug and is included on the World Health Organization's list of essential medicines. Common side effects, which follow from its effects on serotonin and norepinephrine, include nausea, dry mouth, constipation, dizziness, difficulty sleeping, and sweating, and it can produce a modest rise in blood pressure ^[3]. As with other antidepressants of its type, stopping the drug abruptly can cause withdrawal-like discontinuation symptoms, so doses are usually reduced gradually ^[3].

Duloxetine is a prescription antidepressant. Common side effects include nausea, dry mouth, sleepiness or trouble sleeping, constipation, sweating, dizziness, and reduced appetite, and it can dull sexual function. It can nudge blood pressure up and, rarely, injure the liver, so it is avoided in significant liver disease and heavy alcohol use. Stopping it suddenly can trigger dizziness, irritability, and electric-shock sensations, so it should be tapered. It must not be combined with MAOI antidepressants, and pairing it with other serotonergic drugs raises the risk of serotonin syndrome; like all antidepressants it carries a warning about suicidal thoughts in younger people.

Duloxetine is a moderately potent inhibitor of CYP2D6, which causes it to reduce the metabolism of other drugs metabolized by this enzyme. When combined with aripiprazole, duloxetine increases aripiprazole plasma concentrations by approximately 54 percent and dose-adjusted concentrations by 46 percent ^[18]; this is a pharmacokinetic interaction in which duloxetine changes aripiprazole levels. Similarly, duloxetine reduces the clearance of citalopram, resulting in a 4-fold increase in citalopram AUC and a 20-fold increase in peak plasma concentration when the two are coadministered ^[19].

Duloxetine has also been implicated in dangerous serotonergic interactions; a fatal case involved duloxetine combined with amitriptyline and chlorphenamine, all of which inhibit serotonin reuptake, leading to serotonin syndrome and hyponatremia ^[20]. The major interactions remain poorly mapped for codrugs not yet studied; most CYP2D6 substrate drugs have not been formally tested for interactions with duloxetine.

Checking a whole stack? Run it through interactions + stacks.

Duloxetine was developed by Eli Lilly and Company as a balanced serotonin-norepinephrine reuptake inhibitor, growing out of the company's long research program in monoamine pharmacology that had earlier produced fluoxetine. It received United States approval in 2004 and was marketed chiefly under the brand name Cymbalta, first for major depressive disorder and, in the same period, for diabetic peripheral neuropathic pain. Its indications subsequently expanded to generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain, reflecting a distinctive dual role as both an antidepressant and an analgesic.

In some countries a separate formulation was marketed for stress urinary incontinence, exploiting the same enhancement of serotonergic and noradrenergic tone at the level of the sphincter-controlling motor neurons. A landmark randomized trial by Smith and colleagues, published in JAMA in 2013, established its benefit for chemotherapy-induced peripheral neuropathy, and it is now the agent with the strongest randomized evidence recommended by oncology guidelines for that condition. Duloxetine is available generically and appears on the World Health Organization's List of Essential Medicines.

Duloxetine is well regarded for its dual usefulness, treating mood and anxiety disorders while also relieving several chronic pain conditions through its action on the descending pain-modulating pathways of the spinal cord. This makes it especially valuable when depression or anxiety coexists with painful conditions such as diabetic neuropathy, fibromyalgia, or chronic low back pain, allowing a single medication to address both.

It carries the distinction of being the best-supported drug for chemotherapy-induced peripheral neuropathy, a notoriously difficult problem with few effective options. Prescribers appreciate its once-daily dosing and generic availability. In fairness, it can cause nausea, dry mouth, and drowsiness, requires gradual tapering to avoid discontinuation symptoms, and warrants the same monitoring as other antidepressants. On balance it is a versatile, evidence-backed medicine that occupies a useful niche at the intersection of psychiatry and pain management.